LONDON (Reuters) - The pharmaceutical industry is damaging its own business prospects in emerging markets by not doing more to get vital drugs to millions of people in poor countries, international charity Oxfam said on Tuesday.Oxfam said the $700-billion-a-year industry had made “halting progress” in improving access to medicines in the past five years but big drug companies still saw the issue merely as a reputational problem, not a structural one.
